**Let’s Talk Clots ’24 virtual conference for HCPs**

**October 2024**

**Opportunity to submit an e-Poster**

* Delegates who would like to present their work at the Let’s Talk Clots 2024 conference (LTC’24) as a poster are invited to submit a summary abstract for consideration by the LTC’24 Committee by 2nd September 2024.
* There are no fees to submit.
* Abstract summary must be submitted via email to: [jo@thrombosisuk.org](mailto:jo@thrombosisuk.org)
* Abstracts sent by post will not be accepted. No exceptions will be made.

**General Guidelines**

* The summary abstract must address questions or an identified issue, detail clinical observations, or contain primary scientific data.
* The abstract should be submitted in clear English to allow the reviewers to focus on the scientific content. Only abstracts submitted in English can be accepted.
* All research and studies in submitted summaries that involve human subjects or experimental animals must comply with the Declaration of Helsinki.

**Important Dates**

* Monday 2nd September 2024:
  + Abstract submission deadline
* Tuesday 10th September 2024:
  + Abstract titles released (only confirmed participating abstract titles)
* Friday 4th October 2024:
  + Deadline to upload posters to LTC’24 virtual Exhibition Hall

**Main Topics**

* Coagulation & Natural Anticoagulants
* COVID
* Fibrinolysis and Proteolysis
* Haemostatic Systems in Cancer, Inflammation and Immunity
* Immunothrombosis
* Miscellaneous
* Paediatrics
* Patient centred care delivery
* Platelets and Megakaryocytes
* Psychological impact of thrombosis
* Service improvement projects
* Thrombosis and psychiatric care
* Venous Thromboembolism
* Women and thrombosis

To ensure smooth scoring of papers, the topic of your work must be selected during the submission process.

**Preparing your e-Poster, guidance**

All ePosters will be available on-demand on the LTC’24 virtual conference platform.

**Authors and Co-Authors**

* The first/presenting author is responsible for ensuring that all authors have read the poster and agreed to be co-authors.
* The presenting author must be registered for LTC’24 virtual conference. The Poster will be withdrawn if registration is not completed by 4th October 2024.
* Adding Co-authors: please fill out the family names, first names, and institution, city, country and email addresses of each co-author.
* Based on current guidelines, if the presenting author is employed by industry, an alternate presenter who does not have a relevant employment relationship must be named if the poster is selected for presentation in an Oral Communication session.

**Conflict of Interest**

* It is the intent of Thrombosis UK to provide high-quality sessions focused on educational content that is free from commercial influence or bias. Thus, the submitting/presenting author of a poster is required to declare any potential conflicts of interest for the presenting author during submission.

**e-Poster Format:**

* Your e-Poster should be formatted in a PDF as a landscape/horizontal slide that is 16:9 ratio, NOT 4:3. Presenting in 4:3 format may cause your presentation to be distorted. (There is no file size limit)
* Place a heading that runs the full width of the e-Poster at the top in a large-sized type.
* The text should be no less than 8 mm (22 point font) and preferably larger.
* Use a constant font throughout the e-Poster.
* Use a black and bold type to ensure legibility and let your important points stand out.
* We suggest that you show the preferred sequence in which your e-Poster should be reviewed; this can be done by using 3 – 5 columns so the eye movement is down the columns.
* Highlight your main findings. Don’t hide your conclusions, consider putting them at the top of the right column or alternatively start with the Conclusions. Otherwise, we suggest that you structure your e-Poster by Introduction, Methods, Results, and Conclusions. State your aims in the end of the introduction.
* The figures and tables should cover approximately 50% of the e-Poster area.

**Other Recommendations and guidance:**

* If possible, avoid abbreviations and acronyms, especially in the Conclusion section.
* Seek simplicity, keep text to a minimum and avoid redundancies.
* Title: Clearly indicate the nature of the investigation. The poster title and text may not contain trade names. The LTC’24 Committee reserves the right to replace trade names in accepted posters.
* Background
* Aims
* **Methods:** Which should contain sufficient information to be able to understand the experimental design, the analytical techniques and the statistics used in the study
* **Results:** Which should contain objective data to answer the scientific question(s). A maximum of two total tables or figures may be submitted with this section. Please be sure to number each table and figure and cite each table and figure in the poster text.
* **Conclusion (or Conclusions):** Which should provide only conclusions of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralization.
* Other Items for Consideration
  + In clinical studies, please state whether informed consent was obtained and whether the study was approved by a recognized medical ethics committee.
  + If the research included in your Poster was supported by a pharmaceutical or diagnostics company, you can indicate this when submitting your poster.
  + Please indicate the funding agency of your work if applicable. There is not a specific area to enter this information, it will need to be included as part of the poster text.
  + Abbreviations should be defined.
  + If off-label use of a drug was involved in the study, please state this clearly.

**Poster Submission Instructions**

* Do not password protect the file.
* Only submit a one-page PDF.
* If selected, you will receive instructions and a link to upload your e-poster and any accompanying pdf documents and a pre-recorded film of the poster being presented (this is optional).
* You will receive email confirmation when the e-poster has been successfully uploaded. If you do not receive confirmation within 24 hours, please email [jo@thrombosisuk.org](mailto:jo@thrombosisuk.org)

**Any questions - please contact us at**[**jo@thrombosisuk.org**](mailto:jo@thrombosisuk.org)

**After Abstract Submission**

A panel of experts will review submitted summary abstracts. A maximum of four will be selected for oral presentation. The presenting author will be notified at the email address provided during submission.

Authors of Abstracts accepted for display will be notified and will need to follow the same guidance and timelines as indicated.

The reviewers will judge according to the following criteria:

* Is the abstract original?
* Does it address an important area in thrombosis?
* Is the abstract clearly written with all salient facts?
* Does the work adhere to ethical guidelines?
* Is there evidence of statistical method if appropriate?
* Are the conclusions justified by the results?

**Please note:**

* **No revisions can be made after the abstract deadline and then in the poster after the poster deadline.**
* **Poster Presentation:** Authors of posters selected for an oral presentation will be informed about the date and time of the session. **The presenting author will present via the LTC’24 virtual platform and be required to present via zoom at an agreed time. They will also be required to agree to have their presentation recorded and made available on the LTC’24 virtual platform until 30th November 2024.**

**Withdrawal Policy**

If authors wish to withdraw their posters from presentation or publication they are required to notify Thrombosis UK via e-mail to [jo@thrombosisuk.org](mailto:jo@thrombosisuk.org) before Monday 7th October 2024. Withdrawn posters will not be presented nor will these be published.

All ePosters will be available on-demand on the LT’24 virtual conference platform.